pipeline-prospector-insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAd3-SUDV

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $215.5 million Upfront Cash: Undisclosed

            Deal Type: Funding May 13, 2020

            Details:

            This new funding from BARDA will enable Sabin and ReiThera to advance the investigational Ebola Sudan and Marburg vaccines through GMP manufacturing and release of ChAd3-MARV and ChAd3-SUDV Phase 2 clinical trial.